
|Videos|December 3, 2021
Dr. Eggener on active surveillance: “There’s superb long-term outcomes”
Author(s)Urology Times staff
"It’s an important topic to debate,” says Scott E. Eggener, MD.
Advertisement
In this video, Scott Eggener, MD, discusses the key points of the debate, “What is the Preferred Approach for Low Risk Prostate Cancer?” being presented today at the 2021 Society of Urologic Oncology Annual Meeting. Eggener is a Bruce and Beth White Family professor of surgery and radiology, vice chair of the section of urology, and director of the High Risk and Advanced Prostate Cancer Clinic at the University of Chicago Medical Center in Chicago, Illinois.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












